Artificial intelligence startup Tahoe Therapeutics has secured a $30 million investment to develop more efficient AI models for medical research, particularly in oncological research. The funding round was led by Amplify Partners and included Databricks’ venture capital arm, among other institutional backers.
The startup aims to create AI models that can simulate how individual cancer cells behave in different situations, allowing clinicians to quickly test how a cancer cell reacts to various drugs and identify the most effective treatment. To achieve this, Tahoe needs high-quality training data, which is where its platform Mosaic comes into play.
Mosaic generates data by exposing cancer cells to small molecules and collecting data on their reactions. The platform uses scRNA-seq, a newer method that provides significantly more granular data than single-cell transcriptomics. By using Mosaic, Tahoe was able to create the 100 million-strong dataset known as Tahoe-100M.
The company is now planning to use its new funding to develop an even larger training dataset and create AI models that can simulate cancer cells. Co-founder Nima Alidoust said the goal is to bring about a “GPT moment” for AI models of human cells, translating insights into clinical readouts and developing new medicines with lower clinical failure rates.
Down the road, Tahoe plans to collaborate with a drugmaker or AI company to support its training data production efforts. The startup hopes to work with future partners to develop new medicines and reduce clinical trial failures.
Source: https://siliconangle.com/2025/08/11/tahoe-therapeutics-raises-30m-develop-ai-models-medical-research